Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Embracer in connection with a new SEK 3,000,000,000 credit facility
Mandate

Vinge has advised Embracer in connection with a new SEK 3,000,000,000 credit facility

December 18, 2020 Banking and Finance

Vinge has advised Embracer Group AB (publ) in connection with the signing of a new SEK 3,000,000,000 credit facility for, amongst other things, M&A purposes, with Nordea Bank Abp, filial i Sverige.

Embracer Group is the parent company of businesses developing and publishing PC, console and mobile games for the global games market. With its head office based in Karlstad, Sweden, Embracer Group has a global presence through its six operative groups: THQ Nordic GmbH, Koch Media GmbH/Deep Silver, Coffee Stain AB, Amplifier Game Invest, Saber Interactive and DECA Games. The Group has 55 internal game development studios and is engaging more than 5,000 employees and contracted employers in more than 40 countries.

Vinge’s team consisted of Louise Brorsson Salomon, Lionardo Ojeda and Felix Möller.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025